A clinician’s guide to medication assisted treatment for drug addiction
Medically reviewed by Paul Hornsey
Drug addiction is not a matter of choice or moral failing; it is a complex, chronic condition rooted in neuroadaptive changes within the brain. Repeated substance use alters neural pathways, particularly those governing reward, motivation, and executive function, leading to compulsive behaviours and a diminished capacity for self-regulation1
Public figures have begun to shed light on the realities of drug addiction, emphasising its nature as a health issue rather than a personal failing. The Princess of Wales, Kate Middleton, has highlighted the importance of compassion and support for those living with addiction 4.
“For too long, many have suffered in silence, harboring feelings of shame and guilt about their condition, despite their vulnerability.”
Recognising addiction as a neuroadaptive disorder underscores the necessity for comprehensive, evidence-based treatment approaches. Medication assisted treatment (MAT) addresses the physiological aspects of dependence, while psychosocial interventions, such as cognitive-behavioural therapy, target the behavioural and psychological components. Together, these strategies form a whole-person framework essential for effective recovery.
If you have a client who may benefit from medication assisted treatment for drug addiction, contact us to make a referral today.
Medication assisted treatment: mechanisms, modalities, & neurochemical targets
Medication assisted treatment (MAT) refers to the use of FDA-approved pharmacological interventions alongside psychological and behavioural therapies to treat substance use disorders5 – most notably opioid use disorder (OUD). In UK-based clinical settings, this approach is increasingly recognised as a cornerstone of evidence-based addiction treatment, endorsed by NICE6 and supported by public health bodies in the UK7.
MAT addresses the core neurochemical disruptions caused by chronic drug use – not merely suppressing symptoms, but actively stabilising brain function and enabling engagement 8 in psychosocial recovery.
Neurochemical dysregulation in addiction
Chronic exposure to substances like heroin or prescription opioids leads to significant dysregulation in the brain’s reward circuitry 9, particularly:
These adaptations make abrupt abstinence not only intolerable for many patients but neurobiologically unsustainable without clinical support 10.
Neurochemical dysregulation in addiction
Beyond opioids – MAT for other substances
While MAT is most commonly associated with OUD, pharmacotherapies are increasingly applied to alcohol use disorder (eg., acamprosate, disulfiram)15 and emerging trials are exploring utility in stimulant use disorders16. Though results remain mixed17, targeting specific neurotransmitter systems (eg., GABA, glutamate, norepinephrine) continues to inform future protocols.
Clinical indications for MAT
Medication assisted treatment (MAT) is indicated for individuals diagnosed with moderate to severe opioid use disorder (OUD), based on established diagnostic criteria such as those outlined in the DSM-518. MAT may also be appropriate in cases involving:
These adaptations make abrupt abstinence not only intolerable for many patients but neurobiologically unsustainable without clinical support 10.
Contraindications & cautions
While MAT is broadly safe when prescribed appropriately, there are clinical scenarios that may require caution19 or warrant alternative approaches:
A period of abstinence (typically 7–10 days) is required prior to naltrexone initiation to avoid acute withdrawal.
Psychosocial integration
Medication assisted treatment (MAT) is most effective when embedded within a broader, person-centred care plan20 that includes psychosocial support.
Pharmacotherapy addresses neurochemical dysregulation, but it does not resolve the behavioural, psychological, and social drivers of substance use. Without concurrent psychosocial interventions, long-term recovery outcomes are significantly compromised21.
Why integration matters
In addition to the active pharmacological mechanisms that occur within MAT, complementary psychosocial support serves to:
Data consistently shows22 that combining MAT with psychosocial care produces superior outcomes to either modality alone23. NICE, WHO, and SAMHSA all recommend integrated approaches as the gold standard.
Recommended psychosocial modalities
The following therapies are commonly used alongside MAT:
At every stage of the recovery journey, psychosocial integration ensures treatment is not merely about symptom suppression, but about building resilience, restoring autonomy, and supporting long-term reintegration.
Integrating MAT Into multidisciplinary, whole-person care
Ultimately, medication assisted treatment (MAT) should not be viewed as a standalone ‘fix’ – rather, it’s a clinically validated cornerstone of a broader, multidisciplinary approach to treating drug addiction26. When integrated with evidence-based psychosocial interventions, MAT helps stabilise neurobiology, reduce harm, and create space for meaningful psychological and social recovery.
For practitioners, effective implementation means viewing MAT as part of a dynamic, person-centred care model.
As drug-related deaths continue to rise in the UK, the case for expanding MAT access is not just clinical: it is ethical. Reframing MAT as an enabler of long-term recovery, rather than a substitute or crutch, is essential for shifting public perception, health policy, and service delivery.
In the hands of skilled, compassionate teams, MAT becomes more than medication. It becomes an entry point to hope, stability, and the possibility of a life beyond addiction. Contact us now to learn more or to refer a client.
